
Keywords: فسفاتیدیل اینوزیتول; formulation; pharmacokinetics; liposomes; proteins; pharmacodynamics; rhGAA; recombinant human acid α-glucosidase; PI; phosphatidylinositol; FVIII; factor VIII; GAA; acid α-glucosidase; 4-MUG; 4-methylumbelliferyl-α-d-glucopyranoside; PI-rhGAA; PI lipo